Search

Your search keyword '"Walch, Henry"' showing total 338 results
Start Over Author "Walch, Henry"
338 results on '"Walch, Henry"'

4. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

Author

McIntyre, Caitlin A., Grimont, Adrien, Park, Jiwoon, Meng, Yinuo, Sisso, Whitney J., Seier, Kenneth, Jang, Gun Ho, Walch, Henry, Aveson, Victoria G., Falvo, David J., Fall, William B., Chan, Christopher W., Wenger, Andrew, Ecker, Brett L., Pulvirenti, Alessandra, Gelfer, Rebecca, Zafra, Maria Paz, Schultz, Nikolaus, Park, Wungki, O’Reilly, Eileen M., Houlihan, Shauna L., Alonso, Alicia, Hissong, Erika, Church, George M., Mason, Christopher E., Siolas, Despina, Notta, Faiyaz, Gonen, Mithat, Dow, Lukas E., Jarnagin, William R., and Chandwani, Rohit

Published
2024
Full Text
View/download PDF

5. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade

Author

Harrold, Emily C., Foote, Michael B., Rousseau, Benoit, Walch, Henry, Kemel, Yelena, Richards, Allison L., Keane, Fergus, Cercek, Andrea, Yaeger, Rona, Rathkopf, Dana, Segal, Neil H., Patel, Zalak, Maio, Anna, Borio, Matilde, O’Reilly, Eileen M., Reidy, Diane, Desai, Avni, Janjigian, Yelena Y., Murciano-Goroff, Yonina R., Carlo, Maria I., Latham, Alicia, Liu, Ying L., Walsh, Michael F., Ilson, David, Rosenberg, Jonathan E., Markowitz, Arnold J., Weiser, Martin R., Rossi, Anthony M., Vanderbilt, Chad, Mandelker, Diana, Bandlamudi, Chaitanya, Offit, Kenneth, Berger, Michael F., Solit, David B., Saltz, Leonard, Shia, Jinru, Diaz, Jr., Luis A., and Stadler, Zsofia K.

Published
2023
Full Text
View/download PDF

6. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.

Author

Maron, Steven, Moya, Stephanie, Morano, Federica, Emmett, Matthew, Chou, Joanne, Sabwa, Shalom, Walch, Henry, Peterson, Bryan, Schrock, Alexa, Zhang, Liangliang, Janjigian, Yelena, Chalasani, Sree, Ku, Geoffrey, Disel, Umut, Enzinger, Peter, Uboha, Nataliya, Kato, Shumei, Yoshino, Takayuki, Shitara, Kohei, Nakamura, Yoshiaki, Saeed, Anwaar, Kasi, Pashtoon, Chao, Joseph, Lee, Jeeyun, Capanu, Marinela, Petty, Russell, Pietrantonio, Filippo, Klempner, Samuel, Catenacci, Daniel, and Wainberg, Zev

Subjects
Adenocarcinoma, Antibodies, Bispecific, ErbB Receptors, Esophageal Neoplasms, Humans, In Situ Hybridization, Fluorescence, Retrospective Studies, Stomach Neoplasms
Abstract

PURPOSE: Subset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA), but large-scale analyses are lacking. This multi-institutional analysis sought to determine the role of EGFRi in the largest cohort of patients with EGFR-amplified GEA to date. PATIENTS AND METHODS: A total of 60 patients from 15 tertiary cancer centers in six countries met the inclusion criteria. These criteria required histologically confirmed GEA in the metastatic or unresectable setting with EGFR amplification identified by using a Clinical Laboratory Improvement Amendments-approved assay, and who received on- or off-protocol EGFRi. Testing could be by tissue next-generation sequencing, plasma circulating tumor DNA next-generation sequencing, and/or fluorescence in situ hybridization performed by a Clinical Laboratory Improvement Amendments approved laboratory. Treatment patterns and outcomes analysis was also performed using a deidentified clinicogenomic database (CGDB). RESULTS: Sixty patients with EGFR-amplified GEA received EGFRi, including 31 of 60 patients (52%) with concurrent chemotherapy. Across treatment lines, patients achieved a 43% objective response rate with a median progression-free survival of 4.6 months (95% CI, 3.5 to 6.4). Patients receiving EGFRi in first-, second-, and third-line therapy achieved a median overall survival of 20.6 months (95% CI, 13.5 to not reached [NR]), 9 months (95% CI, 7.9 to NR), and 8.4 months (7.6 to NR), respectively. This survival far exceeded the 11.2-month (95% CI, 8.7 to 14.2) median overall survival from first-line initiation of non-EGFRi therapy in patients with EGFR-amplified GEA in the CGDB. Despite this benefit, analysis of the CGDB (January 2011-December 2020) suggests that only 5% of patients with EGFR-amplified GEA received EGFRi. CONCLUSION: Patients with EGFR-amplified GEA derive significant benefit from EGFRi. Further prospective investigation of EGFRi in a well-selected patient population is ongoing in an upcoming trial of amivantamab in EGFR and/or MET amplified GEA.

Published
2022

8. Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

Author

Chatila, Walid K., Walch, Henry, Hechtman, Jaclyn F., Moyer, Sydney M., Sgambati, Valeria, Faleck, David M., Srivastava, Amitabh, Tang, Laura, Benhamida, Jamal, Ismailgeci, Dorina, Campos, Carl, Wu, Fan, Chang, Qing, Vakiani, Efsevia, de Stanchina, Elisa, Weiser, Martin R., Widmar, Maria, Yantiss, Rhonda K., Shah, Manish A., Bass, Adam J., Stadler, Zsofia K., Katz, Lior H., Mellinghoff, Ingo K., Sethi, Nilay S., Schultz, Nikolaus, Ganesh, Karuna, Kelsen, David, and Yaeger, Rona

Published
2023
Full Text
View/download PDF

9. Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

Author

McIntyre, Sarah M., Preston, William A., Walch, Henry, Sharib, Jeremy, Kundra, Ritika, Sigel, Carlie, Lidsky, Michael E., Allen, Peter J., Morse, Michael A., Chen, Wei, Cercek, Andrea, Harding, James J., Abou-Alfa, Ghassan K., OʼReilly, Eileen M., Park, Wungki, Balachandran, Vinod P., Drebin, Jeffrey, Soares, Kevin C., Wei, Alice, Kingham, T. Peter, DʼAngelica, Michael I., Iacobuzio-Donahue, Christine, and Jarnagin, William R.

Published
2024
Full Text
View/download PDF

12. Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib

Author

Miao, Emily, Eichholz, Jordan E., Lebow, Emily S., Flynn, Jessica, Zhang, Zhigang, Walch, Henry, Hubbeling, Harper, Beal, Kathryn, Moss, Nelson S., Yu, Kenny K., Meng, Alicia, Kelly, Daniel W., Gomez, Daniel R., Li, Bob T., Rimner, Andreas, Schultz, Nikolaus, Drilon, Alexander, Imber, Brandon S., and Pike, Luke R.G.

Published
2023
Full Text
View/download PDF

13. Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy

Author

Narayan, Raja R., Datta, Jashodeep, Goldman, Debra A., Aveson, Victoria G., Walch, Henry S., Sanchez-Vega, Francisco, Gönen, Mithat, Balachandran, Vinod P., Drebin, Jeffrey A., Jarnagin, William R., Kingham, T. Peter, Wei, Alice C., Schultz, Nikolaus, Kemeny, Nancy E., and D’Angelica, Michael I.

Published
2022
Full Text
View/download PDF

14. Unique Genomic Alterations and Microbial Profiles Identified in Patients With Gastric Cancer of African, European, and Asian Ancestry: A Novel Path for Precision Oncology

Author

Abate, Miseker, Walch, Henry, Arora, Kanika, Vanderbilt, Chad M., Fei, Teng, Drebin, Harrison, Shimada, Shoji, Maio, Anna, Kemel, Yelena, Stadler, Zsofia K., Schmeltz, Joseph, Sihag, Smita, Ku, Geoffrey Y., Gu, Ping, Tang, Laura, Vardhana, Santosha, Berger, Michael F., Brennan, Murray F., Schultz, Nikolaus D., and Strong, Vivian E.

Published
2023
Full Text
View/download PDF

15. Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II Study

Author

Cowzer, Darren, Wu, Abraham Jing-Ching, Sihag, Smita, Walch, Henry S., Park, Bernard J., Jones, David R., Gu, Ping, Maron, Steven B., Sugarman, Ryan, Chalasani, Sree Bhavani, Shcherba, Marina, Capanu, Marinela, Chou, Joanne F., Choe, Jennie K., Nosov, Anton, Adusumilli, Prasad S., Yeh, Randy, Tang, Laura H., Ilson, David H., Janjigian, Yelena Y., Molena, Daniela, and Ku, Geoffrey Y.

Published
2023
Full Text
View/download PDF

16. A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: the Hidden-Genome Classifier

Author

Song, Yi, primary, Boerner, Thomas, additional, Drill, Esther, additional, Shin, Paul, additional, Kumar, Sandeep, additional, Sigel, Carlie, additional, Cercek, Andrea, additional, Kemeny, Nancy, additional, Abou-Alfa, Ghassan, additional, Iacobuzio-Donahue, Christine, additional, Cowzer, Darren, additional, Schultz, Nikolaus, additional, Walch, Henry, additional, Balachandran, Vinod, additional, Groot Koerkamp, Bas, additional, Kingham, T. Peter., additional, Soares, Kevin, additional, Wei, Alice, additional, D'Angelica, Michael, additional, Drebin, Jeffrey, additional, Chandwani, Rohit, additional, Harding, James, additional, and Jarnagin, William R., additional

Published
2024
Full Text
View/download PDF

17. Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.

Author

Cercek, Andrea, primary, Sinopoli, Jenna Cohen, additional, Shia, Jinru, additional, Weiss, Jill A., additional, Temple, Lindsay, additional, Smith, Jesse Joshua, additional, Saltz, Leonard B., additional, Widmar, Maria, additional, Fumo, Gerard, additional, Aparo, Santiago, additional, Romesser, Paul Bernard, additional, Walch, Henry S., additional, Patel, Mitesh, additional, Jayaprakasam, Vetri Sudar, additional, Kim, Tae-Hyung, additional, Paty, Philip, additional, Gonen, Mithat, additional, Garcia-Aguilar, Julio, additional, Weiser, Martin R., additional, and Diaz, Luis A, additional

Published
2024
Full Text
View/download PDF

18. Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction

Author

Nakauchi, Masaya, primary, Walch, Henry S., additional, Nussenzweig, Samuel, additional, Carr, Rebecca, additional, Vos, Elvira, additional, Berger, Michael F., additional, Schultz, Nikolaus, additional, Janjigian, Yelena, additional, Wu, Abraham, additional, Tang, Laura, additional, Shah, Pari, additional, Jones, David R., additional, Coit, Dan, additional, Strong, Vivian E., additional, Molena, Daniela, additional, and Sihag, Smita, additional

Published
2024
Full Text
View/download PDF

19. Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases.

Author

Khatri, Ishaani S., primary, Eichholz, Jordan, additional, Boe, Lillian A, additional, Safonov, Anton, additional, Smith, Deborah Ruth, additional, Ferraro, Emanuela, additional, Shen, Junchao, additional, Imber, Brandon S., additional, Yu, Yao, additional, Yamada, Yoshiya, additional, Miao, Emily, additional, Moss, Nelson S., additional, Wilcox, Jessica, additional, Walch, Henry S., additional, Chatila, Walid Khaled, additional, Schultz, Nikolaus, additional, Razavi, Pedram, additional, and Pike, Luke R. G., additional

Published
2024
Full Text
View/download PDF

20. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Author

Chatila, Walid K., Kim, Jin K., Walch, Henry, Marco, Michael R., Chen, Chin-Tung, Wu, Fan, Omer, Dana M., Khalil, Danny N., Ganesh, Karuna, Qu, Xuan, Luthra, Anisha, Choi, Seo-Hyun, Ho, Yu-Jui, Kundra, Ritika, Groves, Katharine I., Chow, Oliver S., Cercek, Andrea, Weiser, Martin R., Widmar, Maria, Wei, Iris H., Pappou, Emmanouil P., Nash, Garrett M., Paty, Philip B., Shi, Qian, Vakiani, Efsevia, Duygu Selcuklu, S., Donoghue, Mark T. A., Solit, David B., Berger, Michael F., Shia, Jinru, Pelossof, Raphael, Romesser, Paul B., Yaeger, Rona, Smith, J. Joshua, Schultz, Nikolaus, Sanchez-Vega, Francisco, and Garcia-Aguilar, Julio

Published
2022
Full Text
View/download PDF

21. Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy.

Author

Cowzer, Darren, Chou, Joanne F, Walch, Henry, Keane, Fergus, Khalil, Danny, Shia, Jinru, Do, Richard K G, Yarmohammadi, Hooman, Erinjeri, Joseph P, Dika, Imane El, Yaqubie, Amin, Azhari, Hassan, Gambarin, Maya, Hajj, Carla, Crane, Christopher, Wei, Alice C, Jarnagin, William, Solit, David B, Berger, Michael F, and O'Reilly, Eileen M

Subjects
GENOMICS, RESEARCH funding, IMMUNOTHERAPY, HUMAN beings, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, MEDICAL records, ACQUISITION of data, PROGRESSION-free survival, HEPATITIS C, HEPATOCELLULAR carcinoma, PROPORTIONAL hazards models
Abstract

Introduction Immune checkpoint inhibitor (ICI) combinations extend overall survival (OS) while anti-PD-1/L1 monotherapy is non-inferior to sorafenib in treatment-naïve, patients with advanced hepatocellular carcinoma (HCC). Clinicogenomic features are posited to influence patient outcomes. Methods The primary objective of this retrospective study was to define the clinical, pathologic, and genomic factors associated with outcomes to ICI therapy in patients with HCC. Patients with histologically confirmed advanced HCC treated with ICI at Memorial Sloan Kettering Cancer Center from 2012 to 2022 were included. Association between clinical, pathological, and genomic characteristics were assessed with univariable and multivariable Cox regression model for progression-free survival (PFS) and OS. Results Two-hundred and forty-two patients were treated with ICI-based therapy. Patients were predominantly male (82%) with virally mediated HCC (53%) and Child Pugh A score (70%). Median follow-up was 28 months (0.5-78.4). Median PFS for those treated in 1st line, 2nd line and ≥ 3rd line was 4.9 (range: 2.9-6.2), 3.1 (2.3-4.0), and 2.5 (2.1-4.0) months, respectively. Median OS for those treated in 1st line, 2nd line, and ≥ 3rd line was 16 (11-22), 7.5 (6.4-11), and 6.4 (4.6-26) months, respectively. Poor liver function and performance status associated with worse PFS and OS, while viral hepatitis C was associated with favorable outcome. Genetic alterations were not associated with outcomes. Conclusion Clinicopathologic factors were the major determinates of outcomes for patients with advanced HCC treated with ICI. Molecular profiling did not aid in stratification of ICI outcomes. Future studies should explore alternative biomarkers such as the level of immune activation or the pretreatment composition of the immune tumor microenvironment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.

Author

Keane, Fergus, Chou, Joanne F, Walch, Henry, Schoenfeld, Joshua, Singhal, Anupriya, Cowzer, Darren, Harrold, Emily, O'Connor, Catherine A, Park, Wungki, Varghese, Anna, Dika, Imane El, Balogun, Fiyinfolu, Yu, Kenneth H, Capanu, Marinela, Schultz, Nikolaus, Yaeger, Rona, and O'Reilly, Eileen M

Subjects
PANCREATIC duct, PANCREATIC cancer, RAS oncogenes, BODY mass index, OVERALL survival
Abstract

Background Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed in 1%-2%. Several inhibitors of KRAS G12C have recently demonstrated promise in solid tumors, including pancreatic cancer. Little is known regarding clinical, genomics, and outcome data of this population. Methods Patients with pancreatic cancer and KRAS G12Cmut were identified at Memorial Sloan Kettering Cancer Center and via the American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database. Clinical, treatment, genomic, and outcomes data were analyzed. A cohort of patients at Memorial Sloan Kettering Cancer Center with non-G12C KRAS pancreatic cancer was included for comparison. Results Among 3571 patients with pancreatic ductal adenocarcinoma, 39 (1.1%) with KRAS G12Cmut were identified. Median age was 67 years, and 56% were female. Median body mass index was 29.2 kg/m2, and 67% had a smoking history. Median overall survival was 13 months (95% CI: 9.4 months, not reached) for stage IV and 26 months (95% CI: 23 months, not reached) for stage I-III. Complete genomic data (via American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database) was available for 74 patients. Most common co-alterations included TP53 (73%), CDKN2A (33%), SMAD4 (28%), and ARID1A (21%). Compared with a large cohort (n = 2931) of non-G12C KRAS- mutated pancreatic ductal adenocarcinoma, ARID1A co-mutations were more frequent in KRAS G12Cmut (P  < .05). Overall survival did not differ between KRAS G12Cmut and non-G12C KRAS pancreatic ductal adenocarcinoma. Germline pathogenic variants were identified in 17% of patients; 2 patients received KRAS G12C-directed therapy. Conclusion Pancreatic cancer and KRAS G12Cmut may be associated with a distinct clinical phenotype. Genomic features are similar to non-G12C KRAS- mutated pancreatic cancer, although enrichment of ARID1A co-mutations was observed. Targeting of KRAS G12C in pancreatic cancer provides a precedent for broader KRAS targeting in pancreatic cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study

Author

Boerner, Thomas, Walch, Henry S., Nguyen, Bastien, Iasonos, Alexia, Zhou, Qin C., Schultz, Nikolaus, Chui, M. Herman, Grisham, Rachel N., Tew, William P., O'Cearbhaill, Roisin E., Aghajanian, Carol, Zivanovic, Oliver, Abu-Rustum, Nadeem R., Gardner, Ginger J., Sonoda, Yukio, Chi, Dennis S., and Long Roche, Kara

Published
2021
Full Text
View/download PDF

25. Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options

Author

Ozer, Muhammet, Ranganathan, Megha, Lecomte, Nicolas, Schvartzman, Juan M., Walch, Henry S., Chatila, Walid K., Hong, Jungeui, Carlo, Maria I., Walsh, Michael F., Sheehan, Margaret, Mandelker, Diana, Ceyhan-Birsoy, Ozge, Maio, Anna, Kemel, Yelena, Iacobuzio-Donahue, Christine A., OʼReilly, Eileen M., and Yu, Kenneth H.

Published
2022
Full Text
View/download PDF

26. Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma—Response

Author

Bhatia, Ankush, primary, Moreno, Raquel, additional, Reiner, Anne S., additional, Nandakumar, Subhiksha, additional, Walch, Henry S., additional, Malani, Rachna, additional, Panageas, Katherine S., additional, Mellinghoff, Ingo K., additional, Bale, Tejus A., additional, and Young, Robert J., additional

Published
2024
Full Text
View/download PDF

27. BRAF variants and oncogenic fusions to define sporadic MMR-deficient colorectal cancer subtypes.

Author

Abdelfattah, Somer, primary, Harada, Guilherme, additional, Patel, Shrey, additional, Artz, Oliver, additional, Yaeger, Rona, additional, Johannet, Paul, additional, Harrold, Emily, additional, Walch, Henry S., additional, Argiles, Guillem, additional, Rousseau, Benoit, additional, Stadler, Zsofia Kinga, additional, Cercek, Andrea, additional, Janjigian, Yelena Y., additional, Drilon, Alexander E., additional, Diaz, Luis A., additional, and Foote, Michael Bonner, additional

Published
2024
Full Text
View/download PDF

28. A novel classification of small bowel adenocarcinoma based on a hidden genome classifier: A multi-institutional study.

Author

Schleimer, Lauren E., primary, Ethun, Cecilia Grace, additional, Court, Colin, additional, Chou, Joanne F., additional, McIntyre, Sarah Margaret Helena, additional, Walch, Henry S., additional, Sigel, Carlie S., additional, Sharib, Jeremy, additional, Masoud, Sabran, additional, Chen, Wei, additional, Aveson, Victoria, additional, Wang, Huamin, additional, Katz, Matthew H. G., additional, Overman, Michael J., additional, Lidsky, Michael, additional, Maithel, Shishir K., additional, Poultsides, George A., additional, Fields, Ryan, additional, Gonen, Mithat, additional, and Jarnagin, William R., additional

Published
2024
Full Text
View/download PDF

30. Supplementary Table S1 from Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Author

Randon, Giovanni, primary, Nakamura, Yoshiaki, primary, Yaeger, Rona, primary, Lonardi, Sara, primary, Cremolini, Chiara, primary, Elez, Elena, primary, Nichetti, Federico, primary, Ghelardi, Filippo, primary, Nasca, Vincenzo, primary, Bergamo, Francesca, primary, Conca, Veronica, primary, Ros, Javier, primary, Bando, Hideaki, primary, Maddalena, Giulia, primary, Oldani, Simone, primary, Prisciandaro, Michele, primary, Raimondi, Alessandra, primary, Schrock, Alexa B., primary, Agnelli, Luca, primary, Walch, Henry, primary, Yoshino, Takayuki, primary, and Pietrantonio, Filippo, primary

Published
2024
Full Text
View/download PDF

31. Supplementary Figure S3 from Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Author

Randon, Giovanni, primary, Nakamura, Yoshiaki, primary, Yaeger, Rona, primary, Lonardi, Sara, primary, Cremolini, Chiara, primary, Elez, Elena, primary, Nichetti, Federico, primary, Ghelardi, Filippo, primary, Nasca, Vincenzo, primary, Bergamo, Francesca, primary, Conca, Veronica, primary, Ros, Javier, primary, Bando, Hideaki, primary, Maddalena, Giulia, primary, Oldani, Simone, primary, Prisciandaro, Michele, primary, Raimondi, Alessandra, primary, Schrock, Alexa B., primary, Agnelli, Luca, primary, Walch, Henry, primary, Yoshino, Takayuki, primary, and Pietrantonio, Filippo, primary

Published
2024
Full Text
View/download PDF

32. Data from Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Author

Randon, Giovanni, primary, Nakamura, Yoshiaki, primary, Yaeger, Rona, primary, Lonardi, Sara, primary, Cremolini, Chiara, primary, Elez, Elena, primary, Nichetti, Federico, primary, Ghelardi, Filippo, primary, Nasca, Vincenzo, primary, Bergamo, Francesca, primary, Conca, Veronica, primary, Ros, Javier, primary, Bando, Hideaki, primary, Maddalena, Giulia, primary, Oldani, Simone, primary, Prisciandaro, Michele, primary, Raimondi, Alessandra, primary, Schrock, Alexa B., primary, Agnelli, Luca, primary, Walch, Henry, primary, Yoshino, Takayuki, primary, and Pietrantonio, Filippo, primary

Published
2024
Full Text
View/download PDF

33. Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)

Author

Harrold, Emily, primary, O'Connor, Catherine A., additional, Lin, David, additional, Gazzo, Andrea, additional, Walch, Henry, additional, Ranganathan, Megha, additional, Catchings, Amanda, additional, Kane, Sarah, additional, Keane, Fergus, additional, Thurtle-Schmidt, Deborah M., additional, Balogun, Fiyinfolu, additional, Varghese, Anna, additional, Yu, Kenneth, additional, Kelsen, David, additional, Latham, Alicia, additional, Weigelt, Britta, additional, Park, Wungki, additional, Stadler, Zsofia, additional, and O'Reilly, Eileen M., additional

Published
2024
Full Text
View/download PDF

34. Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

Author

Bhatia, Ankush, primary, Moreno, Raquel, primary, Reiner, Anne S., primary, Nandakumar, Subhiksha, primary, Walch, Henry S., primary, Thomas, Teena M., primary, Nicklin, Philip J., primary, Choi, Ye, primary, Skakodub, Anna, primary, Malani, Rachna, primary, Prabhakaran, Vivek, primary, Tiwari, Pallavi, primary, Diaz, Maria, primary, Panageas, Katherine S., primary, Mellinghoff, Ingo K., primary, Bale, Tejus A., primary, and Young, Robert J., primary

Published
2024
Full Text
View/download PDF

35. Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

Author

Bhatia, Ankush, primary, Moreno, Raquel, primary, Reiner, Anne S., primary, Nandakumar, Subhiksha, primary, Walch, Henry S., primary, Thomas, Teena M., primary, Nicklin, Philip J., primary, Choi, Ye, primary, Skakodub, Anna, primary, Malani, Rachna, primary, Prabhakaran, Vivek, primary, Tiwari, Pallavi, primary, Diaz, Maria, primary, Panageas, Katherine S., primary, Mellinghoff, Ingo K., primary, Bale, Tejus A., primary, and Young, Robert J., primary

Published
2024
Full Text
View/download PDF

36. Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

Author

Bhatia, Ankush, primary, Moreno, Raquel, primary, Reiner, Anne S., primary, Nandakumar, Subhiksha, primary, Walch, Henry S., primary, Thomas, Teena M., primary, Nicklin, Philip J., primary, Choi, Ye, primary, Skakodub, Anna, primary, Malani, Rachna, primary, Prabhakaran, Vivek, primary, Tiwari, Pallavi, primary, Diaz, Maria, primary, Panageas, Katherine S., primary, Mellinghoff, Ingo K., primary, Bale, Tejus A., primary, and Young, Robert J., primary

Published
2024
Full Text
View/download PDF

38. Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

Author

Bhatia, Ankush, primary, Moreno, Raquel, additional, Reiner, Anne S., additional, Nandakumar, Subhiksha, additional, Walch, Henry S., additional, Thomas, Teena M., additional, Nicklin, Philip J., additional, Choi, Ye, additional, Skakodub, Anna, additional, Malani, Rachna, additional, Prabhakaran, Vivek, additional, Tiwari, Pallavi, additional, Diaz, Maria, additional, Panageas, Katherine S., additional, Mellinghoff, Ingo K., additional, Bale, Tejus A., additional, and Young, Robert J., additional

Published
2023
Full Text
View/download PDF

40. RADT-12. GENOMIC CHARACTERISTICS AND CLINICAL OUTCOMES OF STEREOTACTIC RADIOSURGERY FOR COLORECTAL CANCER BRAIN METASTASES

Author

Gui, Chengcheng, primary, Walch, Henry, additional, Mueller, Kirin, additional, Eichholz, Jordan, additional, Khatri, Ishaani, additional, Del Balzo, Luke, additional, Kemeny, Nancy, additional, Imber, Brandon, additional, Schultz, Nikolaus, additional, Foote, Michael, additional, Yaeger, Rona, additional, and Pike, Luke, additional

Published
2023
Full Text
View/download PDF

41. EPCO-01. THE GENOMIC LANDSCAPE OF BRAIN METASTASIS

Author

Skakodub, Anna, primary, Walch, Henry, additional, Kumar, Rahul, additional, Eichholz, Jordan, additional, Cooper, Claire, additional, Khatri, Ishaani, additional, Del Balzo, Luke, additional, Miao, Emily, additional, Gui, Chengcheng, additional, Ma, Jennifer, additional, Tringale, Kathryn, additional, Gaeta, Benjamin, additional, Kelly, Daniel, additional, Moss, Nelson, additional, Yu, Kenny Kwok Hei, additional, Wilcox, Jessica, additional, Bale, Tejus, additional, Yu, Yao, additional, Yamada, Yoshiya, additional, Imber, Brandon, additional, Gomez, Daniel, additional, Schultz, Nikolaus, additional, and Pike, Luke, additional

Published
2023
Full Text
View/download PDF

42. NIMG-38. TUMOR VOLUME GROWTH RATES AND DOUBLING TIMES DURING ACTIVE SURVEILLANCE OF IDH-MUTANT LOW-GRADE GLIOMA

Author

Bhatia, Ankush, primary, Moreno, Raquel, additional, Reiner, Anne, additional, Nandakumar, Subhiksha, additional, Walch, Henry, additional, Thomas, Teena, additional, Nicklin, Philip, additional, Choi, Clara, additional, Skakodub, Anna, additional, Malani, Rachna, additional, Prabhakaran, Vivek, additional, Tiwari, Pallavi, additional, Diaz, Maria, additional, Panageas, Katherine, additional, Mellinghoff, Ingo, additional, Bale, Tejus, additional, and Young, Robert, additional

Published
2023
Full Text
View/download PDF

43. Supplementary Table S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Methods S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure S10 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

46. Data from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

48. Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

Author

Lumish, Melissa A, primary, Walch, Henry, additional, Maron, Steven B, additional, Chatila, Walid, additional, Kemel, Yelena, additional, Maio, Anna, additional, Ku, Geoffrey Y, additional, Ilson, David H, additional, Won, Elizabeth, additional, Li, Jia, additional, Joshi, Smita S, additional, Gu, Ping, additional, Schattner, Mark A, additional, Laszkowska, Monika, additional, Gerdes, Hans, additional, Jones, David R, additional, Sihag, Smita, additional, Coit, Daniel G, additional, Tang, Laura H, additional, Strong, Vivian E, additional, Molena, Daniela, additional, Stadler, Zsofia K, additional, Schultz, Nikolaus, additional, Janjigian, Yelena Y, additional, and Cercek, Andrea, additional

Published
2023
Full Text
View/download PDF

49. Negative hyper-selection of patients with HER2-positive and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study

Author

Randon, Giovanni, primary, Nakamura, Yoshiaki, additional, Yaeger, Rona, additional, Lonardi, Sara, additional, Cremolini, Chiara, additional, Élez, Elena, additional, Nichetti, Federico, additional, Ghelardi, Filippo, additional, Nasca, Vincenzo, additional, Bergamo, Francesca, additional, Conca, Veronica, additional, Ros, Javier, additional, Bando, Hideaki, additional, Maddalena, Giulia, additional, Oldani, Simone, additional, Prisciandaro, Michele, additional, Raimondi, Alessandra, additional, Schrock, Alexa B., additional, Agnelli, Luca, additional, Walch, Henry, additional, Yoshino, Takayuki, additional, and Pietrantonio, Filippo, additional

Published
2023
Full Text
View/download PDF

50. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, additional, Walch, Henry, additional, Chou, Joanne F., additional, Ceglia, Nicholas, additional, Ptashkin, Ryan, additional, Do, Richard Kinh Gian, additional, Paroder, Viktoriya, additional, Pandit-Taskar, Neeta, additional, Lewis, Jason S., additional, Biachi De Castria, Tiago, additional, Sabwa, Shalom, additional, Socolow, Fiona, additional, Feder, Lara, additional, Thomas, Jasmine, additional, Schulze, Isabell, additional, Kim, Kwanghee, additional, Elzein, Arijh, additional, Bojilova, Viktoria, additional, Zatzman, Matthew, additional, Bhanot, Umesh, additional, Nagy, Rebecca J., additional, Lee, Jeeyun, additional, Simmons, Marc, additional, Segal, Michal, additional, Ku, Geoffrey Yuyat, additional, Ilson, David H., additional, Capanu, Marinela, additional, Hechtman, Jaclyn F., additional, Merghoub, Taha, additional, Shah, Sohrab, additional, Schultz, Nikolaus, additional, Solit, David B., additional, and Janjigian, Yelena Y., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results